Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors

Parkinsonism Relat Disord. 2005 Jun:11 Suppl 1:S25-9. doi: 10.1016/j.parkreldis.2004.11.005.

Abstract

Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa therapy for Parkinson's disease. Taking advantage of a monkey brain bank constituted to study the pathophysiology of levodopa-induced dyskinesia, we here report the changes affecting D1, D2 and D3 dopamine receptors within the striatum of four experimental groups of non-human primates: normal, parkinsonian, parkinsonian treated with levodopa without or with dyskinesia. We also report the possible role of arrestin and G protein-coupled receptor kinases.

Publication types

  • Review

MeSH terms

  • Antiparkinson Agents / adverse effects*
  • Dyskinesia, Drug-Induced / etiology*
  • Dyskinesia, Drug-Induced / physiopathology
  • Humans
  • Levodopa / adverse effects*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Receptors, Dopamine D1 / physiology*
  • Receptors, Dopamine D2 / physiology*
  • Receptors, Dopamine D3

Substances

  • Antiparkinson Agents
  • DRD3 protein, human
  • Receptors, Dopamine D1
  • Receptors, Dopamine D2
  • Receptors, Dopamine D3
  • Levodopa